Financhill
Sell
37

BIIB Quote, Financials, Valuation and Earnings

Last price:
$133.51
Seasonality move :
-0.6%
Day range:
$138.72 - $141.56
52-week range:
$138.72 - $238.00
Dividend yield:
0%
P/E ratio:
12.59x
P/S ratio:
2.12x
P/B ratio:
1.24x
Volume:
1.9M
Avg. volume:
1.3M
1-year change:
-42.16%
Market cap:
$20.3B
Revenue:
$9.8B
EPS (TTM):
$11.07

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BIIB
Biogen
$2.4B $3.36 1.22% 101.89% $221.98
ABBV
AbbVie
$14.8B $2.26 5% 227.38% $204.90
LLY
Eli Lilly and
$13.4B $5.07 45.96% 90.83% $979.86
MRNA
Moderna
$941.1M -$2.73 -63.53% -79.68% $62.01
PFE
Pfizer
$17.3B $0.46 -3.36% 28.85% $31.18
SAGE
Sage Therapeutics
$14.4M -$1.36 -81.84% -173.04% $8.64
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BIIB
Biogen
$139.39 $221.98 $20.3B 12.59x $0.00 0% 2.12x
ABBV
AbbVie
$191.83 $204.90 $339B 79.93x $1.64 3.28% 6.03x
LLY
Eli Lilly and
$865.00 $979.86 $777.9B 73.87x $1.30 0.6% 17.36x
MRNA
Moderna
$30.93 $62.01 $11.9B -- $0.00 0% 2.37x
PFE
Pfizer
$25.53 $31.18 $144.7B 18.11x $0.43 6.62% 2.29x
SAGE
Sage Therapeutics
$7.19 $8.64 $439.8M -- $0.00 0% 4.08x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BIIB
Biogen
27.78% 0.011 22.29% 0.68x
ABBV
AbbVie
92.18% 0.524 -- 0.44x
LLY
Eli Lilly and
68.61% 1.194 -- 0.63x
MRNA
Moderna
-- -0.029 -- 3.95x
PFE
Pfizer
41.92% 0.484 -- 0.64x
SAGE
Sage Therapeutics
-- 0.458 -- 9.67x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BIIB
Biogen
$1.8B $496.4M 7.34% 10.52% 20.72% $805.6M
ABBV
AbbVie
$10.7B -$1.5B 5.58% 58.92% -9.87% $5.2B
LLY
Eli Lilly and
$11.1B $5.7B 25.96% 66.4% 41.99% -$458.9M
MRNA
Moderna
$1.3B -$70M -17.44% -17.44% 1.46% -$1.7B
PFE
Pfizer
$11.9B $3.2B 5.04% 4.63% 4.1% $6.1B
SAGE
Sage Therapeutics
$6.6M -$101.2M -48.2% -48.2% -852.52% -$82.4M

Biogen vs. Competitors

  • Which has Higher Returns BIIB or ABBV?

    AbbVie has a net margin of 15.76% compared to Biogen's net margin of -0.15%. Biogen's return on equity of 10.52% beat AbbVie's return on equity of 58.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIIB
    Biogen
    74.1% $2.66 $22.7B
    ABBV
    AbbVie
    70.89% -$0.02 $77.2B
  • What do Analysts Say About BIIB or ABBV?

    Biogen has a consensus price target of $221.98, signalling upside risk potential of 59.25%. On the other hand AbbVie has an analysts' consensus of $204.90 which suggests that it could grow by 6.81%. Given that Biogen has higher upside potential than AbbVie, analysts believe Biogen is more attractive than AbbVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIIB
    Biogen
    13 17 0
    ABBV
    AbbVie
    12 10 0
  • Is BIIB or ABBV More Risky?

    Biogen has a beta of -0.082, which suggesting that the stock is 108.236% less volatile than S&P 500. In comparison AbbVie has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.122%.

  • Which is a Better Dividend Stock BIIB or ABBV?

    Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie offers a yield of 3.28% to investors and pays a quarterly dividend of $1.64 per share. Biogen pays -- of its earnings as a dividend. AbbVie pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIIB or ABBV?

    Biogen quarterly revenues are $2.5B, which are smaller than AbbVie quarterly revenues of $15.1B. Biogen's net income of $388.5M is higher than AbbVie's net income of -$22M. Notably, Biogen's price-to-earnings ratio is 12.59x while AbbVie's PE ratio is 79.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 2.12x versus 6.03x for AbbVie. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIIB
    Biogen
    2.12x 12.59x $2.5B $388.5M
    ABBV
    AbbVie
    6.03x 79.93x $15.1B -$22M
  • Which has Higher Returns BIIB or LLY?

    Eli Lilly and has a net margin of 15.76% compared to Biogen's net margin of 32.59%. Biogen's return on equity of 10.52% beat Eli Lilly and's return on equity of 66.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIIB
    Biogen
    74.1% $2.66 $22.7B
    LLY
    Eli Lilly and
    82.24% $4.88 $45.4B
  • What do Analysts Say About BIIB or LLY?

    Biogen has a consensus price target of $221.98, signalling upside risk potential of 59.25%. On the other hand Eli Lilly and has an analysts' consensus of $979.86 which suggests that it could grow by 13.28%. Given that Biogen has higher upside potential than Eli Lilly and, analysts believe Biogen is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIIB
    Biogen
    13 17 0
    LLY
    Eli Lilly and
    15 6 0
  • Is BIIB or LLY More Risky?

    Biogen has a beta of -0.082, which suggesting that the stock is 108.236% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.369%.

  • Which is a Better Dividend Stock BIIB or LLY?

    Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.6% to investors and pays a quarterly dividend of $1.30 per share. Biogen pays -- of its earnings as a dividend. Eli Lilly and pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIIB or LLY?

    Biogen quarterly revenues are $2.5B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Biogen's net income of $388.5M is lower than Eli Lilly and's net income of $4.4B. Notably, Biogen's price-to-earnings ratio is 12.59x while Eli Lilly and's PE ratio is 73.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 2.12x versus 17.36x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIIB
    Biogen
    2.12x 12.59x $2.5B $388.5M
    LLY
    Eli Lilly and
    17.36x 73.87x $13.5B $4.4B
  • Which has Higher Returns BIIB or MRNA?

    Moderna has a net margin of 15.76% compared to Biogen's net margin of 0.7%. Biogen's return on equity of 10.52% beat Moderna's return on equity of -17.44%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIIB
    Biogen
    74.1% $2.66 $22.7B
    MRNA
    Moderna
    72.29% $0.03 $11.9B
  • What do Analysts Say About BIIB or MRNA?

    Biogen has a consensus price target of $221.98, signalling upside risk potential of 59.25%. On the other hand Moderna has an analysts' consensus of $62.01 which suggests that it could grow by 100.47%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIIB
    Biogen
    13 17 0
    MRNA
    Moderna
    5 15 1
  • Is BIIB or MRNA More Risky?

    Biogen has a beta of -0.082, which suggesting that the stock is 108.236% less volatile than S&P 500. In comparison Moderna has a beta of 1.589, suggesting its more volatile than the S&P 500 by 58.912%.

  • Which is a Better Dividend Stock BIIB or MRNA?

    Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIIB or MRNA?

    Biogen quarterly revenues are $2.5B, which are larger than Moderna quarterly revenues of $1.9B. Biogen's net income of $388.5M is higher than Moderna's net income of $13M. Notably, Biogen's price-to-earnings ratio is 12.59x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 2.12x versus 2.37x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIIB
    Biogen
    2.12x 12.59x $2.5B $388.5M
    MRNA
    Moderna
    2.37x -- $1.9B $13M
  • Which has Higher Returns BIIB or PFE?

    Pfizer has a net margin of 15.76% compared to Biogen's net margin of 2.31%. Biogen's return on equity of 10.52% beat Pfizer's return on equity of 4.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIIB
    Biogen
    74.1% $2.66 $22.7B
    PFE
    Pfizer
    66.73% $0.07 $159.2B
  • What do Analysts Say About BIIB or PFE?

    Biogen has a consensus price target of $221.98, signalling upside risk potential of 59.25%. On the other hand Pfizer has an analysts' consensus of $31.18 which suggests that it could grow by 22.11%. Given that Biogen has higher upside potential than Pfizer, analysts believe Biogen is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIIB
    Biogen
    13 17 0
    PFE
    Pfizer
    7 13 1
  • Is BIIB or PFE More Risky?

    Biogen has a beta of -0.082, which suggesting that the stock is 108.236% less volatile than S&P 500. In comparison Pfizer has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.808%.

  • Which is a Better Dividend Stock BIIB or PFE?

    Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.62% to investors and pays a quarterly dividend of $0.43 per share. Biogen pays -- of its earnings as a dividend. Pfizer pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIIB or PFE?

    Biogen quarterly revenues are $2.5B, which are smaller than Pfizer quarterly revenues of $17.8B. Biogen's net income of $388.5M is lower than Pfizer's net income of $410M. Notably, Biogen's price-to-earnings ratio is 12.59x while Pfizer's PE ratio is 18.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 2.12x versus 2.29x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIIB
    Biogen
    2.12x 12.59x $2.5B $388.5M
    PFE
    Pfizer
    2.29x 18.11x $17.8B $410M
  • Which has Higher Returns BIIB or SAGE?

    Sage Therapeutics has a net margin of 15.76% compared to Biogen's net margin of -788.06%. Biogen's return on equity of 10.52% beat Sage Therapeutics's return on equity of -48.2%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIIB
    Biogen
    74.1% $2.66 $22.7B
    SAGE
    Sage Therapeutics
    55.54% -$1.53 $551.8M
  • What do Analysts Say About BIIB or SAGE?

    Biogen has a consensus price target of $221.98, signalling upside risk potential of 59.25%. On the other hand Sage Therapeutics has an analysts' consensus of $8.64 which suggests that it could grow by 20.13%. Given that Biogen has higher upside potential than Sage Therapeutics, analysts believe Biogen is more attractive than Sage Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIIB
    Biogen
    13 17 0
    SAGE
    Sage Therapeutics
    0 14 0
  • Is BIIB or SAGE More Risky?

    Biogen has a beta of -0.082, which suggesting that the stock is 108.236% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.234%.

  • Which is a Better Dividend Stock BIIB or SAGE?

    Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIIB or SAGE?

    Biogen quarterly revenues are $2.5B, which are larger than Sage Therapeutics quarterly revenues of $11.9M. Biogen's net income of $388.5M is higher than Sage Therapeutics's net income of -$93.6M. Notably, Biogen's price-to-earnings ratio is 12.59x while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 2.12x versus 4.08x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIIB
    Biogen
    2.12x 12.59x $2.5B $388.5M
    SAGE
    Sage Therapeutics
    4.08x -- $11.9M -$93.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 111x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
65
ATEX alert for Feb 12

Anterix [ATEX] is down 0.72% over the past day.

Buy
87
GDS alert for Feb 12

GDS Holdings [GDS] is up 0.32% over the past day.

Sell
30
SPSC alert for Feb 12

SPS Commerce [SPSC] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock